Close Menu

NEW YORK (GenomeWeb) – 23andMe today announced an agreement with drug developer Reset Therapeutics to study the genetics of the circadian clock.

The goal of the collaboration is to develop drug targets for therapeutics that will restore the body's 24-hour physiological rhythms, Reset said in a statement.

Through this collaboration, 23andMe will provide Reset scientists with de-identified, aggregated data from more than 650,000 customers who have consented for their genomic information to be a part of scientific research.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.

The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.

 

University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.

In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.